ARROTEX Pharmaceuticals has launched ARX-Fluticasone (fluticasone furoate) Nasal Spray, the first generic alternative brand of its kind available in Australia for the treatment of seasonal and perennial allergic rhinitis in adults and children aged two years and older.

While ARX-Fluticasone is not on the PBS at this stage, Arrotex expects the generic option to establish a new, lower price point compared to the innovator brand.

Hayley Tamborini, Chief Commercial Officer at Arrotex Pharmaceuticals, said the medication will provide an additional treatment option for around six million Australians living with allergic rhinitis.

“This launch expands choice for doctors and ensures patients have access to a more affordable therapy, particularly families with young children affected by allergic rhinitis who have previously had few options available,” she said.

The post Arrotex launches hayfever drug appeared first on Pharmacy Daily.